pravastatin


Also found in: Dictionary, Thesaurus, Wikipedia.

pravastatin

 [prav´ah-stat″in]
an antihyperlipidemic agent that acts by inhibiting cholesterol synthesis, used as the sodium salt in the treatment of hypercholesterolemia and other forms of dyslipidemia and to lower the risks associated with atherosclerosis and coronary heart disease; administered orally.

pravastatin

/prav·a·stat·in/ (prav´ah-stat″in) an antihyperlipidemic agent that acts by inhibiting cholesterol synthesis, used as the sodium salt in the treatment of hypercholesterolemia and other forms of dyslipidemia and to lower the risks associated with atherosclerosis and coronary heart disease.

pravastatin

(prăv′ə-stăt′n)
n.
A statin, C 23H35NaO7, that blocks the body's synthesis of cholesterol and is administered especially to persons who are at risk for heart disease.

pravastatin

[prav′ahstat′in]
an antihyperlipidemic agent that acts by inhibiting cholesterol synthesis, used as the sodium salt in the treatment of hypercholesterolemia and other forms of dyslipidemia and to lower the risks associated with atherosclerosis and coronary heart disease. It is administered orally.

pravastatin

One of the class of statin cholesterol-lowering drugs. A brand name is Lipostat. See STATINS.

pravastatin (prav´əstat´ən),

n brand name: Pravachol;
drug class: antihyperlipidemic;
action: inhibits HMG-CoA reductase enzyme, which reduces cholesterol synthesis;
use: as an adjunct in primary hypercholesterolemia (types IIa, IIb).
References in periodicals archive ?
Indeed, patients treated with pravastatin for 5 years during the trial gained an average of 5 extra years free of nonfatal MI or cardiovascular death at the 20-year mark, he said.
Additional INTREPID data presented separately from a post-hoc analysis evaluating age as a risk factor for CVD and change in lipid profiles, revealed that over 70% of subjects had age as a risk factor and that pitavastatin 4 mg demonstrated significantly greater reductions in atherogenic lipid parameters (LDL-C, apolipoprotein B, and non-HDL-C) compared with pravastatin 40 mg in men 45 years and older and women age 55 years and older.
Rats were treated daily with pravastatin (brand name - pravachol) or atorvostatin (brand name - Lipitor) for 18 days.
There was a slightly lower absolute risk with simvastatin (26 outcomes per 1 000 person-years) compared with pravastatin (23 outcomes per 1 000 person-years).
Data for secondary endpoints showed LIVALO 4 mg reduced apolipoprotein B (Apo-B), non-HDL-C, and total cholesterol compared with pravastatin 40 mg and improved high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG).
6 mmol/L) (concentrations similar to those of the adult population in the US at the time) to receive placebo or 40 mg pravastatin daily.
2,3) Additionally, in a pivotal Phase III trial in the elderly population (>65 years), pitavastatin demonstrated long-term tolerability (52 weeks) with no serious treatment-emergent adverse event (TEAEs) being attributed to pitavastatin as well as pravastatin.
Fluvastatin is primarily metabolized by 2C9, whereas pravastatin and rosuvastatin are eliminated unchanged by the liver and kidney (21).
Regardless of their telomeres' lengths, men taking pravastatin developed heart disease at the same rate.
Figure 1 describes the monthly marketshares of atorvastatin, simvastatin, and pravastatin in the Texas Medicaid program over a one-year period.
Currently, Sankyo is supplying the bulk drug of pravastatin to Bristol-Myers Squibb (BMS).